SGN-BB228 in Advanced Melanoma and Other Solid Tumors

What is the Purpose of this Study?

The purpose of this study is to evaluate an experimental drug called SGN-BB228 in people with cancer that has come back or did not improve with treatment. SGN-BB228 is designed to find and stick to cancer cells so that it can help the immune cells attack cancer cells. It may also attach to some non-cancer cells in the body. Researchers aim to learn more about the side effects of SGN-BB228 and the best dose of the drug, as well as whether it works to treat certain types of cancers. Participants in this study will have melanoma, lung cancer, colon cancer, pancreatic cancer, or mesothelioma.


Eligibility

  • * All Parts: Participants must have disease that is relapsed, refractory, or intolerant to standard of care. Participants must have histologically or cytologically confirmed metastatic malignancy.
  • * Participants must have one of the following tumor types:
  • * Parts A and B: Participants must have metastatic or unresectable cutaneous melanoma.
Show more

Where can I participate?

Cedars-Sinai Cancer at The Angeles Clinic and Research Institute

More about this Clinical Trial

What is the full name of this clinical trial?

SGNBB228-001: A phase 1 study of SGN-BB228 in advanced melanoma and other solid tumors

Study Details
Disease Type/Condition

Colon, Lung, Melanoma, Pancreas

Principal Investigator

Hamid, Omid

Co-Investigators

Ani Balmanoukian, Cathie T Chung, Inderjit Mehmi, Justin Moyers, Kristopher Wentzel, Navid Hafez, Vi K. Chiu

Age Group

Adult

Phase

I

IRB Number

STUDY00002874

ClinicalTrials.gov ID

NCT05571839

Key Eligibility
ClinicalTrials.gov

How do I learn more about this study?
Email
clinicaltrials@cshs.org
Study Detail
Disease Type/Condition

Colon, Lung, Melanoma, Pancreas

Principal Investigator

Hamid, Omid

Age Group

Adult

Phase

I

IRB Number

SGNBB228-001

ClinicalTrials.gov ID

NCT05571839

Key Eligibility
ClinicalTrials.gov

Contact
Email
clinicaltrials@cshs.org